Aura Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aura Biosciences, Inc. | ||
| Date: March 24, 2025 | By: | /s/ Elisabet de los Pinos |
|---|---|---|
| Elisabet de los Pinos | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Elisabet de los Pinos | President and Chief Executive Officer | March 24, 2025 |
| Elisabet de los Pinos | ||
| /s/ Amy Elazzouzi | Senior Vice President, Finance (Interim Principal Financial Officer and Interim Principal Accounting Officer) | March 24, 2025 |
| Amy Elazzouzi | ||
| /s/ David Johnson | Chairman of the Board of Directors | March 24, 2025 |
| David Johnson | ||
| /s/ Giovanni Mariggi | Director | March 24, 2025 |
| Giovanni Mariggi | ||
| /s/ Antony Mattessich | Director | March 24, 2025 |
| Antony Mattessich | ||
| /s/ Sapna Srivastava | Director | March 24, 2025 |
| Sapna Srivastava | ||
| /s/ Karan Takhar | Director | March 24, 2025 |
| Karan Takhar | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.